Search

Your search keyword '"Dudler J"' showing total 252 results
Start Over Author "Dudler J"
252 results on '"Dudler J"'

1. Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan

Author

Peh, C. Au, Chakera, A., Cooper, B., Kurtkoti, J., Langguth, D., Levidiotis, V., Luxton, G., Mount, P., Mudge, D., Noble, E., Phoon, R., Ranganathan, D., Ritchie, A., Ryan, J., Suranyi, M., Rosenkranz, A., Lhotta, K., Kronbichler, A., Demoulin, N., Bovy, C., Hellemans, R., Hougardy, J., Sprangers, B., Wissing, K., Pagnoux, C., Barbour, S., Brachemi, S., Cournoyer, S., Girard, L., Laurin, L., Liang, P., Philibert, D., Walsh, M., Tesar, V., Becvar, R., Horak, P., Rychlik, I., Szpirt, W., Dieperink, H., Gregersen, J., Ivarsen, P., Krarup, E., Lyngsoe, C., Rigothier, C., Augusto, J., Belot, A., Chauveau, D., Cornec, D., Jourde-Chiche, N., Ficheux, M., Karras, A., Klein, A., Maurier, F., Mesbah, R., Moranne, O., Neel, A., Quemeneur, T., Saadoun, D., Terrier, B., Zaoui, P., Schaier, M., Benck, U., Bergner, R., Busch, M., Floege, J., Grundmann, F., Haller, H., Haubitz, M., Hellmich, B., Henes, J., Hohenstein, B., Hugo, C., Iking-Konert, C., Arndt, F., Kubacki, T., Kotter, I., Lamprecht, P., Lindner, T., Halbritter, J., Mehling, H., Schönermarck, U., Venhoff, N., Vielhauer, V., Witzke, O., Szombati, I., Szucs, G., Garibotto, G., Alberici, F., Brunetta, E., Dagna, L., De Vita, S., Emmi, G., Gabrielli, A., Manenti, L., Pieruzzi, F., Roccatello, D., Salvarani, C., Dobashi, H., Atsumi, T., Fujimoto, S., Hagino, N., Ihata, A., Kaname, S., Kaneko, Y., Katagiri, A., Katayama, M., Kirino, Y., Kitagawa, K., Komatsuda, A., Kono, H., Kurasawa, T., Matsumura, R., Mimura, T., Morinobu, A., Murakawa, Y., Naniwa, T., Nanki, T., Ogawa, N., Oshima, H., Sada, K., Sugiyama, E., Takeuchi, T., Taki, H., Tamura, N., Tsukamoto, T., Yamagata, K., Yamamura, M., van Daele, P., Rutgers, A., Teng, Y., Walker, R., Chua, I., Collins, M., Rabindranath, K., de Zoysa, J., Svensson, M., Grevbo, B., Kalstad, S., Little, M., Clarkson, M., Molloy, E., Pamplona, I. Agraz, Anton, J., Lucia, V. Barrio, Ciggaran, S., Cid, M. Cinta, Encarnacion, M. Diaz, Oliveras, X. Fulladosa, Soler, M. Jose, Rusinol, H. Marco, Praga, M., Porras, L. Quintana, Segarra, A., Bruchfeld, A., Segelmark, M., Soveri, I., Thomaidi, E., Westman, K., Neumann, T., Burnier, M., Daikeler, T., Dudler, J., Hauser, T., Seeger, H., Vogt, B., Jayne, D., Burton, J., Al Jayyousi, R., Amin, T., Andrews, J., Baines, L., Brogan, P., Dasgupta, B., Doulton, T., Flossmann, O., Griffin, S., Harper, J., Harper, L., Kidder, D., Klocke, R., Lanyon, P., Luqmani, R., McLaren, J., Makanjuola, D., McCann, L., Nandagudi, A., Selvan, S., O'Riordan, E., Patel, M., Patel, R., Pusey, C., Rajakariar, R., Robson, J., Robson, M., Salama, A., Smyth, L., Sznajd, J., Taylor, J., Merkel, P., Sreih, A., Belilos, E., Bomback, A., Carlin, J., Chen Lin, Y. Chang, Derebail, V., Dragoi, S., Dua, A., Forbess, L., Geetha, D., Gipson, P., Gohh, R., Greenwood, G.T., Hugenberg, S., Jimenez, R., Kaskas, M., Kermani, T., Kivitz, A., Koening, C., Langford, C., Marder, G., Mohamed, A., Monach, P., Neyra, N., Niemer, G., Niles, J., Obi, R., Owens, C., Parks, D., Podoll, A., Rovin, B., Sam, R., Shergy, W., Silva, A., Specks, U., Spiera, R., Springer, J., Striebich, C., Swarup, A., Thakar, S., Tiliakos, A., Tsai, Y., Waguespack, D., Wasko, M. Chester, Cortazar, Frank B., Niles, John L., Jayne, David R.W., Merkel, Peter A., Bruchfeld, Annette, Yue, Huibin, Schall, Thomas J., and Bekker, Pirow

Published
2023
Full Text
View/download PDF

2. Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan

Author

Cortazar, F, Niles, J, Jayne, D, Merkel, P, Bruchfeld, A, Yue, H, Schall, T, Bekker, P, Peh, C, Chakera, A, Cooper, B, Kurtkoti, J, Langguth, D, Levidiotis, V, Luxton, G, Mount, P, Mudge, D, Noble, E, Phoon, R, Ranganathan, D, Ritchie, A, Ryan, J, Suranyi, M, Rosenkranz, A, Lhotta, K, Kronbichler, A, Demoulin, N, Bovy, C, Hellemans, R, Hougardy, J, Sprangers, B, Wissing, K, Pagnoux, C, Barbour, S, Brachemi, S, Cournoyer, S, Girard, L, Laurin, L, Liang, P, Philibert, D, Walsh, M, Tesar, V, Becvar, R, Horak, P, Rychlik, I, Szpirt, W, Dieperink, H, Gregersen, J, Ivarsen, P, Krarup, E, Lyngsoe, C, Rigothier, C, Augusto, J, Belot, A, Chauveau, D, Cornec, D, Jourde-Chiche, N, Ficheux, M, Karras, A, Klein, A, Maurier, F, Mesbah, R, Moranne, O, Neel, A, Quemeneur, T, Saadoun, D, Terrier, B, Zaoui, P, Schaier, M, Benck, U, Bergner, R, Busch, M, Floege, J, Grundmann, F, Haller, H, Haubitz, M, Hellmich, B, Henes, J, Hohenstein, B, Hugo, C, Iking-Konert, C, Arndt, F, Kubacki, T, Kotter, I, Lamprecht, P, Lindner, T, Halbritter, J, Mehling, H, Schonermarck, U, Venhoff, N, Vielhauer, V, Witzke, O, Szombati, I, Szucs, G, Garibotto, G, Alberici, F, Brunetta, E, Dagna, L, De Vita, S, Emmi, G, Gabrielli, A, Manenti, L, Pieruzzi, F, Roccatello, D, Salvarani, C, Dobashi, H, Atsumi, T, Fujimoto, S, Hagino, N, Ihata, A, Kaname, S, Kaneko, Y, Katagiri, A, Katayama, M, Kirino, Y, Kitagawa, K, Komatsuda, A, Kono, H, Kurasawa, T, Matsumura, R, Mimura, T, Morinobu, A, Murakawa, Y, Naniwa, T, Nanki, T, Ogawa, N, Oshima, H, Sada, K, Sugiyama, E, Takeuchi, T, Taki, H, Tamura, N, Tsukamoto, T, Yamagata, K, Yamamura, M, van Daele, P, Rutgers, A, Teng, Y, Walker, R, Chua, I, Collins, M, Rabindranath, K, de Zoysa, J, Svensson, M, Grevbo, B, Kalstad, S, Little, M, Clarkson, M, Molloy, E, Pamplona, I, Anton, J, Lucia, V, Ciggaran, S, Cid, M, Encarnacion, M, Oliveras, X, Soler, M, Rusinol, H, Praga, M, Porras, L, Segarra, A, Segelmark, M, Soveri, I, Thomaidi, E, Westman, K, Neumann, T, Burnier, M, Daikeler, T, Dudler, J, Hauser, T, Seeger, H, Vogt, B, Burton, J, Al Jayyousi, R, Amin, T, Andrews, J, Baines, L, Brogan, P, Dasgupta, B, Doulton, T, Flossmann, O, Griffin, S, Harper, J, Harper, L, Kidder, D, Klocke, R, Lanyon, P, Luqmani, R, Mclaren, J, Makanjuola, D, Mccann, L, Nandagudi, A, Selvan, S, O'Riordan, E, Patel, M, Patel, R, Pusey, C, Rajakariar, R, Robson, J, Robson, M, Salama, A, Smyth, L, Sznajd, J, Taylor, J, Sreih, A, Belilos, E, Bomback, A, Carlin, J, Chen Lin, Y, Derebail, V, Dragoi, S, Dua, A, Forbess, L, Geetha, D, Gipson, P, Gohh, R, Greenwood, G, Hugenberg, S, Jimenez, R, Kaskas, M, Kermani, T, Kivitz, A, Koening, C, Langford, C, Marder, G, Mohamed, A, Monach, P, Neyra, N, Niemer, G, Obi, R, Owens, C, Parks, D, Podoll, A, Rovin, B, Sam, R, Shergy, W, Silva, A, Specks, U, Spiera, R, Springer, J, Striebich, C, Swarup, A, Thakar, S, Tiliakos, A, Tsai, Y, Waguespack, D, Wasko, M, Cortazar F. B., Niles J. L., Jayne D. R. W., Merkel P. A., Bruchfeld A., Yue H., Schall T. J., Bekker P., Peh C. A., Chakera A., Cooper B., Kurtkoti J., Langguth D., Levidiotis V., Luxton G., Mount P., Mudge D., Noble E., Phoon R., Ranganathan D., Ritchie A., Ryan J., Suranyi M., Rosenkranz A., Lhotta K., Kronbichler A., Demoulin N., Bovy C., Hellemans R., Hougardy J., Sprangers B., Wissing K., Pagnoux C., Barbour S., Brachemi S., Cournoyer S., Girard L., Laurin L., Liang P., Philibert D., Walsh M., Tesar V., Becvar R., Horak P., Rychlik I., Szpirt W., Dieperink H., Gregersen J., Ivarsen P., Krarup E., Lyngsoe C., Rigothier C., Augusto J., Belot A., Chauveau D., Cornec D., Jourde-Chiche N., Ficheux M., Karras A., Klein A., Maurier F., Mesbah R., Moranne O., Neel A., Quemeneur T., Saadoun D., Terrier B., Zaoui P., Schaier M., Benck U., Bergner R., Busch M., Floege J., Grundmann F., Haller H., Haubitz M., Hellmich B., Henes J., Hohenstein B., Hugo C., Iking-Konert C., Arndt F., Kubacki T., Kotter I., Lamprecht P., Lindner T., Halbritter J., Mehling H., Schonermarck U., Venhoff N., Vielhauer V., Witzke O., Szombati I., Szucs G., Garibotto G., Alberici F., Brunetta E., Dagna L., De Vita S., Emmi G., Gabrielli A., Manenti L., Pieruzzi F., Roccatello D., Salvarani C., Dobashi H., Atsumi T., Fujimoto S., Hagino N., Ihata A., Kaname S., Kaneko Y., Katagiri A., Katayama M., Kirino Y., Kitagawa K., Komatsuda A., Kono H., Kurasawa T., Matsumura R., Mimura T., Morinobu A., Murakawa Y., Naniwa T., Nanki T., Ogawa N., Oshima H., Sada K., Sugiyama E., Takeuchi T., Taki H., Tamura N., Tsukamoto T., Yamagata K., Yamamura M., van Daele P., Rutgers A., Teng Y., Walker R., Chua I., Collins M., Rabindranath K., de Zoysa J., Svensson M., Grevbo B., Kalstad S., Little M., Clarkson M., Molloy E., Pamplona I. A., Anton J., Lucia V. B., Ciggaran S., Cid M. C., Encarnacion M. D., Oliveras X. F., Soler M. J., Rusinol H. M., Praga M., Porras L. Q., Segarra A., Segelmark M., Soveri I., Thomaidi E., Westman K., Neumann T., Burnier M., Daikeler T., Dudler J., Hauser T., Seeger H., Vogt B., Jayne D., Burton J., Al Jayyousi R., Amin T., Andrews J., Baines L., Brogan P., Dasgupta B., Doulton T., Flossmann O., Griffin S., Harper J., Harper L., Kidder D., Klocke R., Lanyon P., Luqmani R., McLaren J., Makanjuola D., McCann L., Nandagudi A., Selvan S., O'Riordan E., Patel M., Patel R., Pusey C., Rajakariar R., Robson J., Robson M., Salama A., Smyth L., Sznajd J., Taylor J., Merkel P., Sreih A., Belilos E., Bomback A., Carlin J., Chen Lin Y. C., Derebail V., Dragoi S., Dua A., Forbess L., Geetha D., Gipson P., Gohh R., Greenwood G. T., Hugenberg S., Jimenez R., Kaskas M., Kermani T., Kivitz A., Koening C., Langford C., Marder G., Mohamed A., Monach P., Neyra N., Niemer G., Niles J., Obi R., Owens C., Parks D., Podoll A., Rovin B., Sam R., Shergy W., Silva A., Specks U., Spiera R., Springer J., Striebich C., Swarup A., Thakar S., Tiliakos A., Tsai Y., Waguespack D., Wasko M. C., Cortazar, F, Niles, J, Jayne, D, Merkel, P, Bruchfeld, A, Yue, H, Schall, T, Bekker, P, Peh, C, Chakera, A, Cooper, B, Kurtkoti, J, Langguth, D, Levidiotis, V, Luxton, G, Mount, P, Mudge, D, Noble, E, Phoon, R, Ranganathan, D, Ritchie, A, Ryan, J, Suranyi, M, Rosenkranz, A, Lhotta, K, Kronbichler, A, Demoulin, N, Bovy, C, Hellemans, R, Hougardy, J, Sprangers, B, Wissing, K, Pagnoux, C, Barbour, S, Brachemi, S, Cournoyer, S, Girard, L, Laurin, L, Liang, P, Philibert, D, Walsh, M, Tesar, V, Becvar, R, Horak, P, Rychlik, I, Szpirt, W, Dieperink, H, Gregersen, J, Ivarsen, P, Krarup, E, Lyngsoe, C, Rigothier, C, Augusto, J, Belot, A, Chauveau, D, Cornec, D, Jourde-Chiche, N, Ficheux, M, Karras, A, Klein, A, Maurier, F, Mesbah, R, Moranne, O, Neel, A, Quemeneur, T, Saadoun, D, Terrier, B, Zaoui, P, Schaier, M, Benck, U, Bergner, R, Busch, M, Floege, J, Grundmann, F, Haller, H, Haubitz, M, Hellmich, B, Henes, J, Hohenstein, B, Hugo, C, Iking-Konert, C, Arndt, F, Kubacki, T, Kotter, I, Lamprecht, P, Lindner, T, Halbritter, J, Mehling, H, Schonermarck, U, Venhoff, N, Vielhauer, V, Witzke, O, Szombati, I, Szucs, G, Garibotto, G, Alberici, F, Brunetta, E, Dagna, L, De Vita, S, Emmi, G, Gabrielli, A, Manenti, L, Pieruzzi, F, Roccatello, D, Salvarani, C, Dobashi, H, Atsumi, T, Fujimoto, S, Hagino, N, Ihata, A, Kaname, S, Kaneko, Y, Katagiri, A, Katayama, M, Kirino, Y, Kitagawa, K, Komatsuda, A, Kono, H, Kurasawa, T, Matsumura, R, Mimura, T, Morinobu, A, Murakawa, Y, Naniwa, T, Nanki, T, Ogawa, N, Oshima, H, Sada, K, Sugiyama, E, Takeuchi, T, Taki, H, Tamura, N, Tsukamoto, T, Yamagata, K, Yamamura, M, van Daele, P, Rutgers, A, Teng, Y, Walker, R, Chua, I, Collins, M, Rabindranath, K, de Zoysa, J, Svensson, M, Grevbo, B, Kalstad, S, Little, M, Clarkson, M, Molloy, E, Pamplona, I, Anton, J, Lucia, V, Ciggaran, S, Cid, M, Encarnacion, M, Oliveras, X, Soler, M, Rusinol, H, Praga, M, Porras, L, Segarra, A, Segelmark, M, Soveri, I, Thomaidi, E, Westman, K, Neumann, T, Burnier, M, Daikeler, T, Dudler, J, Hauser, T, Seeger, H, Vogt, B, Burton, J, Al Jayyousi, R, Amin, T, Andrews, J, Baines, L, Brogan, P, Dasgupta, B, Doulton, T, Flossmann, O, Griffin, S, Harper, J, Harper, L, Kidder, D, Klocke, R, Lanyon, P, Luqmani, R, Mclaren, J, Makanjuola, D, Mccann, L, Nandagudi, A, Selvan, S, O'Riordan, E, Patel, M, Patel, R, Pusey, C, Rajakariar, R, Robson, J, Robson, M, Salama, A, Smyth, L, Sznajd, J, Taylor, J, Sreih, A, Belilos, E, Bomback, A, Carlin, J, Chen Lin, Y, Derebail, V, Dragoi, S, Dua, A, Forbess, L, Geetha, D, Gipson, P, Gohh, R, Greenwood, G, Hugenberg, S, Jimenez, R, Kaskas, M, Kermani, T, Kivitz, A, Koening, C, Langford, C, Marder, G, Mohamed, A, Monach, P, Neyra, N, Niemer, G, Obi, R, Owens, C, Parks, D, Podoll, A, Rovin, B, Sam, R, Shergy, W, Silva, A, Specks, U, Spiera, R, Springer, J, Striebich, C, Swarup, A, Thakar, S, Tiliakos, A, Tsai, Y, Waguespack, D, Wasko, M, Cortazar F. B., Niles J. L., Jayne D. R. W., Merkel P. A., Bruchfeld A., Yue H., Schall T. J., Bekker P., Peh C. A., Chakera A., Cooper B., Kurtkoti J., Langguth D., Levidiotis V., Luxton G., Mount P., Mudge D., Noble E., Phoon R., Ranganathan D., Ritchie A., Ryan J., Suranyi M., Rosenkranz A., Lhotta K., Kronbichler A., Demoulin N., Bovy C., Hellemans R., Hougardy J., Sprangers B., Wissing K., Pagnoux C., Barbour S., Brachemi S., Cournoyer S., Girard L., Laurin L., Liang P., Philibert D., Walsh M., Tesar V., Becvar R., Horak P., Rychlik I., Szpirt W., Dieperink H., Gregersen J., Ivarsen P., Krarup E., Lyngsoe C., Rigothier C., Augusto J., Belot A., Chauveau D., Cornec D., Jourde-Chiche N., Ficheux M., Karras A., Klein A., Maurier F., Mesbah R., Moranne O., Neel A., Quemeneur T., Saadoun D., Terrier B., Zaoui P., Schaier M., Benck U., Bergner R., Busch M., Floege J., Grundmann F., Haller H., Haubitz M., Hellmich B., Henes J., Hohenstein B., Hugo C., Iking-Konert C., Arndt F., Kubacki T., Kotter I., Lamprecht P., Lindner T., Halbritter J., Mehling H., Schonermarck U., Venhoff N., Vielhauer V., Witzke O., Szombati I., Szucs G., Garibotto G., Alberici F., Brunetta E., Dagna L., De Vita S., Emmi G., Gabrielli A., Manenti L., Pieruzzi F., Roccatello D., Salvarani C., Dobashi H., Atsumi T., Fujimoto S., Hagino N., Ihata A., Kaname S., Kaneko Y., Katagiri A., Katayama M., Kirino Y., Kitagawa K., Komatsuda A., Kono H., Kurasawa T., Matsumura R., Mimura T., Morinobu A., Murakawa Y., Naniwa T., Nanki T., Ogawa N., Oshima H., Sada K., Sugiyama E., Takeuchi T., Taki H., Tamura N., Tsukamoto T., Yamagata K., Yamamura M., van Daele P., Rutgers A., Teng Y., Walker R., Chua I., Collins M., Rabindranath K., de Zoysa J., Svensson M., Grevbo B., Kalstad S., Little M., Clarkson M., Molloy E., Pamplona I. A., Anton J., Lucia V. B., Ciggaran S., Cid M. C., Encarnacion M. D., Oliveras X. F., Soler M. J., Rusinol H. M., Praga M., Porras L. Q., Segarra A., Segelmark M., Soveri I., Thomaidi E., Westman K., Neumann T., Burnier M., Daikeler T., Dudler J., Hauser T., Seeger H., Vogt B., Jayne D., Burton J., Al Jayyousi R., Amin T., Andrews J., Baines L., Brogan P., Dasgupta B., Doulton T., Flossmann O., Griffin S., Harper J., Harper L., Kidder D., Klocke R., Lanyon P., Luqmani R., McLaren J., Makanjuola D., McCann L., Nandagudi A., Selvan S., O'Riordan E., Patel M., Patel R., Pusey C., Rajakariar R., Robson J., Robson M., Salama A., Smyth L., Sznajd J., Taylor J., Merkel P., Sreih A., Belilos E., Bomback A., Carlin J., Chen Lin Y. C., Derebail V., Dragoi S., Dua A., Forbess L., Geetha D., Gipson P., Gohh R., Greenwood G. T., Hugenberg S., Jimenez R., Kaskas M., Kermani T., Kivitz A., Koening C., Langford C., Marder G., Mohamed A., Monach P., Neyra N., Niemer G., Niles J., Obi R., Owens C., Parks D., Podoll A., Rovin B., Sam R., Shergy W., Silva A., Specks U., Spiera R., Springer J., Striebich C., Swarup A., Thakar S., Tiliakos A., Tsai Y., Waguespack D., and Wasko M. C.

Abstract

Introduction: In the 330-patient ADVOCATE trial of avacopan for the treatment of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, in which 81% of patients had renal involvement, estimated glomerular filtration rate (eGFR) increased on average 7.3 ml/min per 1.73 m2 in the avacopan group and 4.1 ml/min per 1.73 m2 in the prednisone group (P = 0.029) at week 52. This new analysis examines the results in the patient subgroup with severe renal insufficiency at enrollment into the trial, i.e., eGFR ≤20 ml/min per 1.73 m2. Methods: eGFR was determined at baseline and over the course of the trial. Changes in eGFR were compared between the 2 treatment groups. Results: In ADVOCATE, 27 of 166 patients (16%) in the avacopan group and 23 of 164 patients (14%) in the prednisone group had a baseline eGFR ≤20 ml/min per 1.73 m2. At week 52, eGFR increased on average 16.1 and 7.7 ml/min per 1.73 m2 in the avacopan and prednisone groups, respectively (P = 0.003). The last eGFR value measured during the 52-week treatment period was ≥2-fold higher than baseline in 41% of patients in the avacopan group compared to 13% in the prednisone group (P = 0.030). More patients in the avacopan group versus prednisone group had increases in eGFR above 20, 30, and 45 ml/min per 1.73 m2, respectively. Serious adverse events occurred in 13 of 27 patients (48%) in the avacopan group and 16 of 23 patients (70%) in the prednisone group. Conclusion: Among patients with baseline eGFR ≤20 ml/min per 1.73 m2 in the ADVOCATE trial, eGFR improved more in the avacopan group than in the prednisone group.

Published
2023

4. Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan

Author

Cortazar, Frank B., primary, Niles, John L., additional, Jayne, David R.W., additional, Merkel, Peter A., additional, Bruchfeld, Annette, additional, Yue, Huibin, additional, Schall, Thomas J., additional, Bekker, Pirow, additional, Peh, C. Au, additional, Chakera, A., additional, Cooper, B., additional, Kurtkoti, J., additional, Langguth, D., additional, Levidiotis, V., additional, Luxton, G., additional, Mount, P., additional, Mudge, D., additional, Noble, E., additional, Phoon, R., additional, Ranganathan, D., additional, Ritchie, A., additional, Ryan, J., additional, Suranyi, M., additional, Rosenkranz, A., additional, Lhotta, K., additional, Kronbichler, A., additional, Demoulin, N., additional, Bovy, C., additional, Hellemans, R., additional, Hougardy, J., additional, Sprangers, B., additional, Wissing, K., additional, Pagnoux, C., additional, Barbour, S., additional, Brachemi, S., additional, Cournoyer, S., additional, Girard, L., additional, Laurin, L., additional, Liang, P., additional, Philibert, D., additional, Walsh, M., additional, Tesar, V., additional, Becvar, R., additional, Horak, P., additional, Rychlik, I., additional, Szpirt, W., additional, Dieperink, H., additional, Gregersen, J., additional, Ivarsen, P., additional, Krarup, E., additional, Lyngsoe, C., additional, Rigothier, C., additional, Augusto, J., additional, Belot, A., additional, Chauveau, D., additional, Cornec, D., additional, Jourde-Chiche, N., additional, Ficheux, M., additional, Karras, A., additional, Klein, A., additional, Maurier, F., additional, Mesbah, R., additional, Moranne, O., additional, Neel, A., additional, Quemeneur, T., additional, Saadoun, D., additional, Terrier, B., additional, Zaoui, P., additional, Schaier, M., additional, Benck, U., additional, Bergner, R., additional, Busch, M., additional, Floege, J., additional, Grundmann, F., additional, Haller, H., additional, Haubitz, M., additional, Hellmich, B., additional, Henes, J., additional, Hohenstein, B., additional, Hugo, C., additional, Iking-Konert, C., additional, Arndt, F., additional, Kubacki, T., additional, Kotter, I., additional, Lamprecht, P., additional, Lindner, T., additional, Halbritter, J., additional, Mehling, H., additional, Schönermarck, U., additional, Venhoff, N., additional, Vielhauer, V., additional, Witzke, O., additional, Szombati, I., additional, Szucs, G., additional, Garibotto, G., additional, Alberici, F., additional, Brunetta, E., additional, Dagna, L., additional, De Vita, S., additional, Emmi, G., additional, Gabrielli, A., additional, Manenti, L., additional, Pieruzzi, F., additional, Roccatello, D., additional, Salvarani, C., additional, Dobashi, H., additional, Atsumi, T., additional, Fujimoto, S., additional, Hagino, N., additional, Ihata, A., additional, Kaname, S., additional, Kaneko, Y., additional, Katagiri, A., additional, Katayama, M., additional, Kirino, Y., additional, Kitagawa, K., additional, Komatsuda, A., additional, Kono, H., additional, Kurasawa, T., additional, Matsumura, R., additional, Mimura, T., additional, Morinobu, A., additional, Murakawa, Y., additional, Naniwa, T., additional, Nanki, T., additional, Ogawa, N., additional, Oshima, H., additional, Sada, K., additional, Sugiyama, E., additional, Takeuchi, T., additional, Taki, H., additional, Tamura, N., additional, Tsukamoto, T., additional, Yamagata, K., additional, Yamamura, M., additional, van Daele, P., additional, Rutgers, A., additional, Teng, Y., additional, Walker, R., additional, Chua, I., additional, Collins, M., additional, Rabindranath, K., additional, de Zoysa, J., additional, Svensson, M., additional, Grevbo, B., additional, Kalstad, S., additional, Little, M., additional, Clarkson, M., additional, Molloy, E., additional, Pamplona, I. Agraz, additional, Anton, J., additional, Lucia, V. Barrio, additional, Ciggaran, S., additional, Cid, M. Cinta, additional, Encarnacion, M. Diaz, additional, Oliveras, X. Fulladosa, additional, Soler, M. Jose, additional, Rusinol, H. Marco, additional, Praga, M., additional, Porras, L. Quintana, additional, Segarra, A., additional, Bruchfeld, A., additional, Segelmark, M., additional, Soveri, I., additional, Thomaidi, E., additional, Westman, K., additional, Neumann, T., additional, Burnier, M., additional, Daikeler, T., additional, Dudler, J., additional, Hauser, T., additional, Seeger, H., additional, Vogt, B., additional, Jayne, D., additional, Burton, J., additional, Al Jayyousi, R., additional, Amin, T., additional, Andrews, J., additional, Baines, L., additional, Brogan, P., additional, Dasgupta, B., additional, Doulton, T., additional, Flossmann, O., additional, Griffin, S., additional, Harper, J., additional, Harper, L., additional, Kidder, D., additional, Klocke, R., additional, Lanyon, P., additional, Luqmani, R., additional, McLaren, J., additional, Makanjuola, D., additional, McCann, L., additional, Nandagudi, A., additional, Selvan, S., additional, O'Riordan, E., additional, Patel, M., additional, Patel, R., additional, Pusey, C., additional, Rajakariar, R., additional, Robson, J., additional, Robson, M., additional, Salama, A., additional, Smyth, L., additional, Sznajd, J., additional, Taylor, J., additional, Merkel, P., additional, Sreih, A., additional, Belilos, E., additional, Bomback, A., additional, Carlin, J., additional, Chen Lin, Y. Chang, additional, Derebail, V., additional, Dragoi, S., additional, Dua, A., additional, Forbess, L., additional, Geetha, D., additional, Gipson, P., additional, Gohh, R., additional, Greenwood, G.T., additional, Hugenberg, S., additional, Jimenez, R., additional, Kaskas, M., additional, Kermani, T., additional, Kivitz, A., additional, Koening, C., additional, Langford, C., additional, Marder, G., additional, Mohamed, A., additional, Monach, P., additional, Neyra, N., additional, Niemer, G., additional, Niles, J., additional, Obi, R., additional, Owens, C., additional, Parks, D., additional, Podoll, A., additional, Rovin, B., additional, Sam, R., additional, Shergy, W., additional, Silva, A., additional, Specks, U., additional, Spiera, R., additional, Springer, J., additional, Striebich, C., additional, Swarup, A., additional, Thakar, S., additional, Tiliakos, A., additional, Tsai, Y., additional, Waguespack, D., additional, and Wasko, M. Chester, additional

Published
2023
Full Text
View/download PDF

8. Avacopan for the Treatment of ANCA-Associated Vasculitis

Author

Jayne, David R W, Merkel, Peter A, Schall, Thomas J, Bekker, Pirow, ADVOCATE Study Group:, C Au Peh, Chakera, A, Cooper, B, Kurtkoti, J, Langguth, D, Levidiotis, V, Luxton, G, Mount, P, Mudge, D, Noble, E, Phoon, R, Ranganathan, D, Ritchie, A, Ryan, J, Suranyi, M, Rosenkranz, A, Lhotta, K, Kronbichler, A, Demoulin, N, Bovy, C, Hellemans, R, Hougardy, J, Sprangers, B, Wissing, K, Pagnoux, C, Barbour, S, Brachemi, S, Cournoyer, S, Girard, L, Laurin, L, Liang, P, Philibert, D, Walsh, M, Tesar, V, Becvar, R, Horak, P, Rychlik, I, Szpirt, W, Dieperink, H, Gregersen, J, Ivarsen, P, Krarup, E, Lyngsoe, C, Rigothier, C, Augusto, J, Belot, A, Chauveau, D, Cornec, D, Jourde-Chiche, N, Ficheux, M, Karras, A, Klein, A, Maurier, F, Mesbah, R, Moranne, O, Neel, A, Quemeneur, T, Saadoun, D, Terrier, B, Zaoui, P, Schaier, M, Benck, U, Bergner, R, Busch, M, Floege, J, Grundmann, F, Haller, H, Haubitz, M, Hellmich, B, Henes, J, Hohenstein, B, Hugo, C, Iking-Konert, C, Arndt, F, Kubacki, T, Kotter, I, Lamprecht, P, Lindner, T, Halbritter, J, Mehling, H, Schönermarck, U, Venhoff, N, Vielhauer, V, Witzke, O, Szombati, I, Szucs, G, Garibotto, G, Alberici, F, Brunetta, E, Dagna, L, S De Vita, Emmi, G, Gabrielli, A, Manenti, L, Pieruzzi, F, Roccatello, D, Salvarani, C, Dobashi, H, Atsumi, T, Fujimoto, S, Hagino, N, Ihata, A, Kaname, S, Kaneko, Y, Katagiri, A, Katayama, M, Kirino, Y, Kitagawa, K, Komatsuda, A, Kono, H, Kurasawa, T, Matsumura, R, Mimura, T, Morinobu, A, Murakawa, Y, Naniwa, T, Nanki, T, Ogawa, N, Oshima, H, Sada, K, Sugiyama, E, Takeuchi, T, Taki, H, Tamura, N, Tsukamoto, T, Yamagata, K, Yamamura, M, P van Daele, Rutgers, A, Teng, Y, Walker, R, Chua, I, Collins, M, Rabindranath, K, J de Zoysa, Svensson, M, Grevbo, B, Kalstad, S, Little, M, Clarkson, M, Molloy, E, I Agraz Pamplona, Anton, J, V Barrio Lucia, Ciggaran, S, M Cinta Cid, M Diaz Encarnacion, X Fulladosa Oliveras, M Soler, J, H Rusinol, M, Praga, M, L Quintana Porras, Segarra, A, Bruchfeld, A, Segelmark, M, Soveri, I, Thomaidi, E, Westman, K, Neumann, T, Burnier, M, Daikeler, T, Dudler, J, Hauser, T, Seeger, H, Vogt, B, Jayne, D, Burton, J, R Al Jayyousi, Amin, T, Andrews, J, Baines, L, Brogan, P, Dasgupta, B, Doulton, T, Flossmann, O, Griffin, S, Harper, J, Harper, L, Kidder, D, Klocke, R, Lanyon, P, Luqmani, R, Mclaren, J, Makanjuola, D, Mccann, L, Nandagudi, A, Selvan, S, O'Riordan, E, Patel, M, Patel, R, Pusey, C, Rajakariar, R, Robson, J, Robson, M, Salama, A, Smyth, L, Sznajd, J, Taylor, J, Merkel, P, Sreih, A, Belilos, E, Bomback, A, Carlin, J, Y Chang Chen Lin, Derebail, V, Dragoi, S, Dua, A, Forbess, L, Geetha, D, Gipson, P, Gohh, R, T Greenwood, G, Hugenberg, S, Jimenez, R, Kaskas, M, Kermani, T, Kivitz, A, Koening, C, Langford, C, Marder, G, Mohamed, A, Monach, P, Neyra, N, Niemer, G, Niles, J, Obi, R, Owens, C, Parks, D, Podoll, A, Rovin, B, Sam, R, Shergy, W, Silva, A, Specks, U, Spiera, R, Springer, J, Striebich, C, Swarup, A, Thakar, S, Tiliakos, A, Tsai, Y, Waguespack, D, M Chester Wasko, Internal Medicine, Immunology, Jayne, D, Merkel, P, Schall, T, Bekker, P, Pieruzzi, F, Jayne, David RW [0000-0002-1712-0637], Apollo - University of Cambridge Repository, and Translational Immunology Groningen (TRIGR)

Subjects
Male, Receptor, Anaphylatoxin C5a/antagonists & inhibitors, Anaphylatoxin C5a, Anaphylatoxin C5a/antagonists & inhibitors, Nipecotic Acids, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculiti, Administration, Oral, Azathioprine, Kaplan-Meier Estimate, 030204 cardiovascular system & hematology, urologic and male genital diseases, Gastroenterology, C5a receptor, Cyclophosphamide/administration & dosage, Rituximab/administration & dosage, Immunosuppressive Agent, renal vasculitis, Prednisone/administration & dosage, 0302 clinical medicine, Glucocorticoid, immune system diseases, Prednisone, Recurrence, Medicine, 030212 general & internal medicine, skin and connective tissue diseases, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/drug therapy, Aniline Compounds, Remission Induction, General Medicine, Aniline Compound, Middle Aged, Administration, Combination, Rituximab, Drug Therapy, Combination, Female, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Cyclophosphamide, Double-Blind Method, Glucocorticoids, Humans, Immunosuppressive Agents, Receptor, Anaphylatoxin C5a, Vasculitis, Receptor, medicine.drug, Human, Azathioprine/administration & dosage, Oral, medicine.medical_specialty, Nipecotic Acid, ANCA-Associated Vasculitis, 03 medical and health sciences, Drug Therapy, Internal medicine, Aniline Compounds/adverse effects, cardiovascular diseases, Immunosuppressive Agents/administration & dosage, Anti-neutrophil cytoplasmic antibody, business.industry, Glucocorticoids/administration & dosage, medicine.disease, Nipecotic Acids/adverse effects, respiratory tract diseases, business
Abstract

BACKGROUND: The C5a receptor inhibitor avacopan is being studied for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.METHODS: In this randomized, controlled trial, we assigned patients with ANCA-associated vasculitis in a 1:1 ratio to receive oral avacopan at a dose of 30 mg twice daily or oral prednisone on a tapering schedule. All the patients received either cyclophosphamide (followed by azathioprine) or rituximab. The first primary end point was remission, defined as a Birmingham Vasculitis Activity Score (BVAS) of 0 (on a scale from 0 to 63, with higher scores indicating greater disease activity) at week 26 and no glucocorticoid use in the previous 4 weeks. The second primary end point was sustained remission, defined as remission at both weeks 26 and 52. Both end points were tested for noninferiority (by a margin of 20 percentage points) and for superiority.RESULTS: A total of 331 patients underwent randomization; 166 were assigned to receive avacopan, and 165 were assigned to receive prednisone. The mean BVAS at baseline was 16 in both groups. Remission at week 26 (the first primary end point) was observed in 120 of 166 patients (72.3%) receiving avacopan and in 115 of 164 patients (70.1%) receiving prednisone (estimated common difference, 3.4 percentage points; 95% confidence interval [CI], -6.0 to 12.8; PCONCLUSIONS: In this trial involving patients with ANCA-associated vasculitis, avacopan was noninferior but not superior to prednisone taper with respect to remission at week 26 and was superior to prednisone taper with respect to sustained remission at week 52. All the patients received cyclophosphamide or rituximab. The safety and clinical effects of avacopan beyond 52 weeks were not addressed in the trial. (Funded by ChemoCentryx; ADVOCATE ClinicalTrials.gov number, NCT02994927.).

Published
2021

13. Efficacy and safety of baricitinib versus placebo and adalimumab in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate: Summary results from the 52-week phase 3 RA-beam study

Author

Taylor, P, Krogulec, M, Dudek, A, Dudler, J, Drescher, E, Cseuz, R, Kausiene, R, Andersone, D, Unikiene, D, Sanchez Burson, J, Blanco Alonso, R, Dvorak, Z, Ghizdavescu, A, Irto, I, Larsson, E, Bello, N, Barry, J, Durand, F, Holzkaemper, T, Otawa, S, De Bono, S, Keystone, E, Rubbert-Roth, A, Combe, B, and De La Torre, I

Published
2019
Full Text
View/download PDF

16. DEKAVIL (F8IL10): A novel therapeutic approach for the treatment of rheumatoid arthritis

Author

Voll, R, Bannert, B, Finzel, S, Specker, C, Wollenhaupt, J, Galeazzi, M, Selvi, E, Sebastiani, G, Dudler, J, Bootz, F, Neri, D, and DEKAVIL Study Group

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Background: The antibody-based targeted pharmacodelivery of cytokines by means of immunocytokines has the potential to enhance therapeutic activity at the site of disease while sparing healthy tissues. Dekavil (F8IL10) is a fully human immunocytokine composed of the vascular targeting antibody F8 (specific[for full text, please go to the a.m. URL], 45. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 31. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), 27. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2017
Full Text
View/download PDF

20. SAT0692 Breastfeeding is not associated with anti-citrullinated antibodies development in individuals at risk for rheumatoid arthritis

Author

Alpizar-Rodriguez, D., primary, Ruediger, M., additional, Möller, B., additional, Dudler, J., additional, Ciurea, A., additional, Zufferey, P., additional, Kyburz, D., additional, Walker, U., additional, von Mühlenen, I., additional, Roux-Lombard, P., additional, Lamacchia, C., additional, Gabay, C., additional, and Finckh, A., additional

Published
2018
Full Text
View/download PDF

21. Can one or two high doses of oral vitamin D3 correct insufficiency in a non-supplemented rheumatologic population?

Author

Stoll, D., Dudler, J., Lamy, O., Hans, D., Krieg, M., Aubry-Rozier, B., Stoll, D., Dudler, J., Lamy, O., Hans, D., Krieg, M., and Aubry-Rozier, B.

Abstract

Summary: We evaluated the effectiveness of supplementation with high dose of oral vitamin D3 to correct vitamin D insufficiency. We have shown that one or two oral bolus of 300,000IU of vitamin D3 can correct vitamin D insufficiency in 50% of patients and that the patients who benefited more from supplementation were those with the lowest baseline levels. Introduction: Adherence with daily oral supplements of vitamin D3 is suboptimal. We evaluated the effectiveness of a single high dose of oral vitamin D3 (300,000IU) to correct vitamin D insufficiency in a rheumatologic population. Methods: Over 1month, 292 patients had levels of 25-OH vitamin D determined. Results were classified as: deficiency <10ng/ml, insufficiency ≥10 to 30ng/ml, and normal ≥30ng/ml. We added a category using the IOM recommended cut-off of 20ng/ml. Patients with deficient or normal levels were excluded, as well as patients already supplemented with vitamin D3. Selected patients (141) with vitamin D insufficiency (18.5ng/ml (10.2-29.1) received a prescription for 300,000IU of oral vitamin D3 and were asked to return after 3 (M3) and 6months (M6). Patients still insufficient at M3 received a second prescription for 300,000IU of oral vitamin D3. Relation between changes in 25-OH vitamin D between M3 and M0 and baseline values were assessed. Results: Patients (124) had a blood test at M3. Two (2%) had deficiency (8.1ng/ml (7.5-8.7)) and 50 (40%) normal results (36.7ng/ml (30.5-5.5)). Seventy-two (58%) were insufficient (23.6ng/ml (13.8-29.8)) and received a second prescription for 300,000IU of oral vitamin D3. Of the 50/124 patients who had normal results at M3 and did not receive a second prescription, 36 (72%) had a test at M6. Seventeen (47%) had normal results (34.8ng/ml (30.3-42.8)) and 19 (53%) were insufficient (25.6ng/ml (15.2-29.9)). Of the 72/124 patients who receive a second prescription, 54 (75%) had a test at M6. Twenty-eight (52%) had insufficiency (23.2ng/ml (12.8-28.7)) and 26 (48%)

Published
2018

23. CPPD crystal deposition disease in patients with rheumatoid arthritis

Author

Gerster, J., Varisco, P., Kern, J., Dudler, J., So, A., Gerster, J., Varisco, P., Kern, J., Dudler, J., and So, A.

Abstract

The aim of this study was to assess the frequency and the outcome of patients suffering from rheumatoid arthritis in which calcium pyrophosphate dihydrate (CPPD) crystal deposits were found to coexist in synovial fluid analysis. Such association was more frequent than previously believed with CPPD crystals found in 25.8% of 93 patients with rheumatoid arthritis. As a group, a trend toward a worse outcome was suggested by more frequent prostheses of the lower limb

Published
2018

25. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

Author

Finckh, A, Ciurea, A, Brulhart, L, Möller, B, Walker, U A, Courvoisier, D, Kyburz, D, Dudler, J, Gabay, C, and Arthritis, on the behalf of the doctors of the Swiss Clinical Quality Management Programme for Rheumatoid

Subjects
Oncology, Male, Severity of Illness Index, Arthritis, Rheumatoid, Antibodies, Monoclonal, Murine-Derived, 0302 clinical medicine, Immunopathology, Immunology and Allergy, 030212 general & internal medicine, Antirheumatic Agents/*therapeutic use, Prospective Studies, Treatment Failure, Prospective cohort study, Clinical and epidemiological research, ddc:616, Antibodies, Monoclonal, Middle Aged, Connective tissue disease, Arthritis, Rheumatoid/*drug therapy, 3. Good health, Treatment Outcome, Rheumatoid arthritis, Antirheumatic Agents, Rituximab, Female, medicine.drug, medicine.medical_specialty, Tumor Necrosis Factor-alpha/*antagonists & inhibitors, Immunology, Antibodies, Monoclonal/*therapeutic use, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, Rheumatology, Internal medicine, Severity of illness, medicine, Humans, 030203 arthritis & rheumatology, Autoimmune disease, business.industry, Tumor Necrosis Factor-alpha, Patient Selection, medicine.disease, Antigens, CD20, business, Antigens, CD20/immunology
Abstract

Background:Patients with rheumatoid arthritis (RA) with an inadequate response to TNF antagonists (aTNFs) may switch to an alternative aTNF or start treatment from a different class of drugs, such as rituximab (RTX). It remains unclear in which clinical settings these therapeutic strategies offer most benefit.Objective:To analyse the effectiveness of RTX versus alternative aTNFs on RA disease activity in different subgroups of patients.Methods:A prospective cohort study of patients with RA who discontinued at least one aTNF and subsequently received either RTX or an alternative aTNF, nested within the Swiss RA registry (SCQM-RA) was carried out. The primary outcome, longitudinal improvement in 28-joint count Disease Activity Score (DAS28), was analysed using multivariate regression models for longitudinal data and adjusted for potential confounders.Results:Of the 318 patients with RA included; 155 received RTX and 163 received an alternative aTNF. The relative benefit of RTX varied with the type of prior aTNF failure: when the motive for switching was ineffectiveness to previous aTNFs, the longitudinal improvement in DAS28 was significantly better with RTX than with an alternative aTNF (p = 0.03; at 6 months, −1.34 (95% CI −1.54 to −1.15) vs −0.93 (95% CI −1.28 to −0.59), respectively). When the motive for switching was other causes, the longitudinal improvement in DAS28 was similar for RTX and alternative aTNFs (p = 0.40). These results were not significantly modified by the number of previous aTNF failures, the type of aTNF switches, or the presence of co-treatment with a disease-modifying antirheumatic drug.Conclusion:This observational study suggests that in patients with RA who have stopped a previous aTNF treatment because of ineffectiveness changing to RTX is more effective than switching to an alternative aTNF.

Published
2009

26. AB1114 Patient's self-monitoring of disease activity of rheumatic diseases via webapp – study design, patient's perspective and recruitment in the first 11 months of the swiss multicentre, longitudinal compass ii study

Author

Jaeger, VK, primary, Schiffer, P, additional, Zufferey, P, additional, Pichler, L, additional, Badaracco, A, additional, Walder, M, additional, Dudler, J, additional, Frey, D, additional, Müller, F, additional, and Walker, UA, additional

Published
2017
Full Text
View/download PDF

27. Efficacy and safety of baricitinib versus placebo and adalimumab in patients with moderately-to-severely active rheumatoid arthritis and inadequate response to methotrexate (MTX-IR): summary results from the 52-week phase 3 RA-BEAM study

Author

Taylor, P, Krogulec, M, Dudek, A, Dudler, J, Drescher, E, Cseuz, R, Kausiene, R, Andersone, D, Unikiene, D, Burson, JS, Alonso, RB, Dvorák, Z, Petru Ghizdavescu, A, Irto, I, Larsson, E, Bello, N, Barry, J, Durand, F, Holzkämper, T, Otawa, S, de Bono, S, Keystone, E, Rubbert-Roth, A, Combe, B, de la Torre, I, Taylor, P, Krogulec, M, Dudek, A, Dudler, J, Drescher, E, Cseuz, R, Kausiene, R, Andersone, D, Unikiene, D, Burson, JS, Alonso, RB, Dvorák, Z, Petru Ghizdavescu, A, Irto, I, Larsson, E, Bello, N, Barry, J, Durand, F, Holzkämper, T, Otawa, S, de Bono, S, Keystone, E, Rubbert-Roth, A, Combe, B, and de la Torre, I

Published
2017

30. BARICITINIBE VS. PBO E ADALIMUMABE NA ARTRITE REUMATOIDE MOD A GRAVE ‐ RESULTADOS DO RA‐BEAM

Author

Taylor, P.C., primary, Krogulec, M., additional, Dudek, A., additional, Dudler, J., additional, Drescher, E., additional, Cseuz, R., additional, Kausiene, R., additional, Andersone, D., additional, Unikiene, D., additional, Burson, J.S., additional, Alonso, R.B., additional, Dvořák, Z., additional, Ghizdavescu, A., additional, Irto, I., additional, Larsson, E., additional, Bello, N., additional, Barry, J., additional, Durand, F., additional, Holzkämper, T., additional, Otawa, S., additional, de Bono, S., additional, Keystone, E.C., additional, Rubbert-Roth, A., additional, Combe, B., additional, De La Torre, I., additional, and Gonçalves, L.F., additional

Published
2017
Full Text
View/download PDF

31. AB0178 Menopause Is A Predictor for The Development of Anti-Citrullinated Protein Antibodies in Women at Risk for Rheumatoid Arthritis

Author

Alpizar-Rodriguez, D., primary, Müller, R., additional, Möller, B., additional, Dudler, J., additional, Ciurea, A., additional, Von Mühlenen, I., additional, Kyburz, D., additional, Zufferey, P., additional, Bas, S., additional, Gascon, D., additional, Lamacchia, C., additional, Roux-Lombard, P., additional, Lauper, K., additional, Courvoisier, D., additional, Gabay, C., additional, and Finckh, A., additional

Published
2016
Full Text
View/download PDF

32. FRI0071 Predictors for The Development of anti-Citrullinated Protein Antibodies in Individuals Genetically at Risk for Rheumatoid Arthritis

Author

Alpizar-Rodriguez, D., primary, Brulhart, L., additional, Müller, R., additional, Möller, B., additional, Dudler, J., additional, Ciurea, A., additional, Walker, U., additional, Von Mühlenen, I., additional, Kyburz, D., additional, Zufferey, P., additional, Mahler, M., additional, Bas, S., additional, Gascon, D., additional, Lamacchia, C., additional, Roux-Lombard, P., additional, Lauper, K., additional, Nissen, M., additional, Courvoisier, D., additional, Gabay, C., additional, and Finckh, A., additional

Published
2016
Full Text
View/download PDF

33. AB0364 A Novel Approach for Rheumatoid Arthritis: Results of The Ongoing Clinical Trials with The Fully Human Immunocytokine Dekavil (F8-IL10)

Author

Galeazzi, M., primary, Voll, R., additional, Sebastiani, G., additional, Bazzichi, L., additional, Viapiana, O., additional, Dudler, J., additional, Sarzi-Puttini, P., additional, Selvi, E., additional, Iuliano, A., additional, Pedretti, M., additional, Giovannoni, L., additional, Bindi, I., additional, Bettini, C., additional, Ravenni, N., additional, Wilton, J., additional, Zufferey, P., additional, Ferraccioli, G., additional, Caporali, R., additional, Specker, C., additional, Wollenhaupt, J., additional, and Neri, D., additional

Published
2016
Full Text
View/download PDF

37. A novel screening strategy for preclinical rheumatoid arthritis (RA) in first degree relatives of patients with RA

Author

Finckh A Müller RB Möller B Dudler J Kyburz D Walker UA Bas S Liang MH Gabay C

Abstract

[2011] [THU0314] A NOVEL SCREENING STRATEGY FOR PRECLINICAL RHEUMATOID ARTHRITIS (RA) IN FIRST DEGREE RELATIVES OF PATIENTS WITH RA A. Finckh1 R.B. Müller2 B. Möller3 J. Dudler4 D. Kyburz5 U. Walker6 S. Bas1 M. Liang7 C. Gabay1 1Rheumatology Geneva University Hospital Geneva; 2Kantonsspital St Gallen; 3University Hospital of Bern (Inselspital); 4Rheumatology University Hospital of Vaud (CHUV) Fribourg Hospital Fribourg; 5Rheumatology University Hospital of Zurich (USZ); 6Rheumatology University Hospital of Basel Switzerland; 7Rheumatology Brigham Women's Hospital Boston United States Background: The contemporary view of the pathophysiology of rheumatoid arthritis (RA) is a process that starts with a pathologic activation of the adaptive immune system (or 'immune onset of the disease') followed by an asymptomatic period (or 'preclinical phase') eventually leading to the 'clinical onset of the disease'. Biomarkers and clinical risk factors of pre symptomatic disease exist and suggest that screening at risk populations for early detection of RA and treatment are not out of the realm of the possible. Objectives: To describe a multicenter cohort of first degree relatives (FDRs)of RA patients and to analyse the prevalence of auto AB in this healthy population. Methods: This is an ongoingprospective cohort study of individuals at increased risk of developing RA namely FDRs of patients with active RA. Only individuals without clinical evidence of synovitis are enrolled and than followed up yearly to detect the development of symptoms of arthritis. The overall aim of the study is to evaluate the feasibility of a screening strategy in a population at increased risk of developing RA. Demographic physical examination data and autoantibody status from the inclusion visit are described. Results: A total of 302 FDRs of RA patients are analysed. At inclusion mean age is 41 years (SD 15) 75 are female 93 are Caucasian median duration of education is 13 years (IQR:12 – 16) median BMI is 23 (IQR: 21 – 26). On average these individuals have 1.3 direct relatives with RA and 15 present at least one tender joint on examination. 18 of FDRs had at least one positive auto Ab: 14 were positive for rheumatoid factor IgM 3 were positive for rheumatoid factor IgA and 1 had anti–cyclic citrullinated peptide antibodies (anti CCP 2 or 3.1). High levels of auto Ab or simultaneous positivity of several autoAB were rare in this population (N=1). Individuals with at least one positive auto Ab were at higher risk to present tender joints on examination (OR: 3.23 95 CI: 1.10 9.52). Conclusions: The prevalence of auto AB positivity among FDRs is somewhat higher than what would be expected in a younger general population suggesting that FDRs are indeed a group at higher risk of developing RA. The association between positive auto Ab and joint tenderness suggests that auto Ab are a valid intermediate marker of RA development in this population. Prospective FDR cohorts will be will be a valuable resource to decipher RA development and the relationship between genetic and environmental risk factors. Disclosure of Interest: None Declared Citation: Ann Rheum Dis 2011;70(Suppl3):282

Published
2011

38. Biologics in rheumatoid arthritis - recommendations for Swiss practice

Author

Dudler, J., Möller, B., Michel, B.A., and Villiger, P.

Subjects
musculoskeletal diseases, rheumatoid arthritis, biologics, anti-TNF, treatment optimisation, guidelines, CONTROLLED-TRIAL, DOUBLE-BLIND, COMBINATION THERAPY, METHOTREXATE, MULTICENTER, OUTCOMES, AGENT, ETANERCEPT, INHIBITION, RITUXIMAB
Abstract

The new paradigm of therapy in rheumatoid arthritis is to aim toward early and complete remission, using a larger use of conventional DMARDs and biologic agents. The present recommendations were established through a consensus to help practitioners in their daily use of those agents, to reflect the current "best practice" in Switzerland.

Published
2011

39. A single high dose of oral vitamin D3 is insufficient to correct a deficiency in a rheumatologic population

Author

Stoll, D., Lamy, O., Krieg, M.A., Hans, D., Dudler, J., So, A., and Aubry-Rozier, B.

Abstract

Introduction Vitamin D plays a major role in bone metabolismand neuromuscular function. Supplementation with vitamin D iseffective to reduce the risk of fall and of fracture. However adherenceto oral daily vitamin D is low. Screening and correcting vitamin Dinsufficiency in a rheumatologic population could improve bothmorbidity and quality of life. After determining the prevalence ofvitamin D deficiency in this population, we evaluated if supplementationwith a single high dose of oral 25-OH vitamin D3 wassufficient to correct this abnormality.Methods During one month (November 2009), levels of 25-OHvitamin D were systematically determined in our rheumatology outpatientclinic and classified in: vitamin D deficiency (< 10 μg/l),vitamin D insufficiency (10 to 30 μg/l) or normal vitamin D (> 30 μg/l).Patients with insufficiency or deficiency received respectively a singlehigh dose of 300'000 IU or 600'000 IU oral vitamin D3. In addition,all patients with osteoporosis were prescribed daily supplement ofcalcium (1 g) and vitamin D (800 IU). 25-OH vitamin D levels werereevaluated after 3 months.Results Vitamin D levels were initially determined in 292 patients(mean age 53, 211 women, 87 % Caucasian). 77 % had inflammatoryrheumatologic disease (IRD), 20 % osteoporosis (OP) and 12 %degenerative disease (DD). Vitamin D deficiency was present in 20(6.8 %), while 225 (77.1 %) had insufficiency. Of the 245 patientswith levels < 30μg/l, a new determination of vitamin D level wasavailable in 173 (71 %) at 3 months.Conclusion Vitamin D insufficiency is highly prevalent in ourrheumatologic population (84 %), and is not adequately correctedby a single high dose of oral vitamin D3 in > 50 % of the patientswith IRD and DD. In patients with OP, despite association of asingle high dose with daily oral vitamin D supplementation, 40 %of patients are still deficient when reevaluated at 3 months.

Published
2011

41. AB0251 Female Reproductive Factors and the Development of Anti-Citrullinated Protein Antibodies in Women at Risk of Rheumatoid Arthritis

Author

Alpizar-Rodriguez, D., primary, Mueller, R.B., additional, Möller, B., additional, Dudler, J., additional, Ciurea, A., additional, Zufferey, P., additional, Kyburz, D., additional, Walker, U.A., additional, Von Mühlenen, I., additional, Cornelis, F., additional, Bas, S., additional, Roux-Lombard, P., additional, Gabay, C., additional, and Finckh, A., additional

Published
2015
Full Text
View/download PDF

42. OP0166 Antibodies Against Periodontal Pathogens are not Associated with Joint Swelling or Autoimmunity Associated with RA in a Cohort of Healthy Individuals at Increased Risk of Rheumatoid Arthritis

Author

Finckh, A., primary, Mueller, R.B., additional, Dudler, J., additional, Moeller, B., additional, Kyburz, D., additional, Walker, U., additional, Von Muehlenen, I., additional, Bas, S., additional, Gabay, C., additional, and Bostanci, N., additional

Published
2015
Full Text
View/download PDF

43. Which subgroup of rheumatoid arthritis patients benefits from switching to rituximab versus alternative anti-TNF agents after previous failure to anti-TNF agent?

Author

Finckh, A, Ciurea, A, Brulhart, L, Möller, B, Walker, U A, Courvoisier, D, Kyburz, D, Dudler, J, Gabay, C, University of Zurich, and Finckh, A

Subjects
2403 Immunology, 1300 General Biochemistry, Genetics and Molecular Biology, 2745 Rheumatology, 10051 Rheumatology Clinic and Institute of Physical Medicine, 2723 Immunology and Allergy, 610 Medicine & health
Published
2010
Full Text
View/download PDF

44. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

Author

Smolen, Js, Beaulieu, A, Rubbert Roth, A, Ramos Remus, C, Rovensky, J, Alecock, E, Woodworth, T, Alten, R, Tate, G, Maldonado Cocco JA, Scali, J, Taylor, A, Hanrahan, P, Nash, P, Smith, M, Smolen, J, Koeller, M, Eberl, G, Dunky, A, Zamani, O, Simon, Jc, Scheinberg, Ma, Yaneva, D, Oparanov, B, Karastatev, D, Atkins, C, Bell, M, Haraoui, B, Marin, L, Thorne, Jc, Zummer, M, Khraishi, M, Mckendry, Rj, Pandith, V, Mccarthy, T, Lau, Cs, Li, E, Mok, Cc, Kahan, A, Wendling, D, Bardin, T, Nguyen, M, Claudepierre, P, Berenbaum, F, Puechal, X, Fiehn, C, Heilig, B, Hellmich, B, Lange, U, Lorenz, Hm, Wendler, J, Czirijak, L, Hodinka, L, Szekanecz, Z, Molad, Y, Nahir, M, Rosner, I, Rubinow, A, Abu Shakra, M, Elkayam, O, Marcolongo, R, Bagnato, G, Triolo, G, Trotta, F, DE VITA, Salvatore, Lugo, Ge, Abud Mendoza, C, Pineca, C, de la Torre IG, Pacheco, C, Leong, Kh, Koh, Dr, Dudler, J, Villiger, P, Lothrenoo, W, Asavatanabodee, P, Nilganuwong, S, and Totemchokchaiyakarn, K.

Subjects
rheumatoid arthritis, interleukin-6
Published
2008

45. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents

Author

Finckh, A, Ciurea, A, Brulhart, L, Kyburz, D, Möller, B, Dehler, S, Revaz, S, Dudler, J, Gabay, C, University of Zurich, and Finckh, A

Subjects
2403 Immunology, Rheumatology, 2745 Rheumatology, Immunology, 2723 Immunology and Allergy, 2736 Pharmacology (medical), Immunology and Allergy, 610 Medicine & health, Pharmacology (medical), 10060 Epidemiology, Biostatistics and Prevention Institute (EBPI)
Published
2007
Full Text
View/download PDF

47. THU0238 Risk Factors for the Development of Anti-Citrullinated Protein Antibodies in Individuals Genetically at Risk for RA

Author

Finckh, A., primary, Debost-Legrand, A., additional, Müller, R., additional, Möller, B., additional, Dudler, J., additional, Ciurea, A., additional, Walker, U.A., additional, Zufferey, P., additional, Kyburz, D., additional, Bas, S., additional, Dubost, J.-J., additional, Crevaux, I., additional, Von Mühlenen, I., additional, Soubrier, M., additional, Cornelis, F., additional, Gabay, C., additional, and Migliorini, P., additional

Published
2014
Full Text
View/download PDF

48. Swiss consensus statement: Recommendations for optimising re-treatment with MabThera (rituximab) in rheumatoid arthritis

Author

Dudler, J, Finckh, A, Kyburz, D, Langenegger, T, Möller, B, Schmiedel, U, Walker, U A, Dudler, J, Finckh, A, Kyburz, D, Langenegger, T, Möller, B, Schmiedel, U, and Walker, U A

Abstract

Rituximab is an effective treatment of rheumatoid arthritis (RA), which has been approved for the treatment of moderate to severe disease in patients with an inadequate response to anti-TNF therapies. Rituximab differs from other available biological agents for RA by way of its unique mode of action and unrivalled long dosing interval. The efficacy of rituximab subsides progressively over time and re-therapy is generally required to maintain long term disease control. The timing of re-treatment is currently not well established and varies widely in clinical practice. The present document is a concise recommendation regarding re-treatment with rituximab, based on validated outcomes such as the DAS28 and the EULAR response criteria. The recommendation was established through consensus between practitioners familiar with rituximab therapy in RA. Optimisation of the rituximab re-treatment schedule may improve patient outcomes and balance risks and benefits for the individual patient.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results